Yifen Shi

1.1k citations
33 papers · 888 indexed · 1 hit paper · h-index 14
Topics
Lymphoma Diagnosis and Treatment (7 papers)Cancer-related molecular mechanisms research (4 papers)Acute Myeloid Leukemia Research (4 papers)

In The Last Decade

Yifen Shi

31 papers receiving 880 citations

Hit Papers

Exosome secreted from adipose-derived stem cells attenuat...2019202620212023201950100150200250

Peers

Yifen Shi
Comparison fields: 5 of 94
  • Molecular Biology 429
  • Cancer Research 239
  • Hematology 181
  • Surgery 149
  • Epidemiology 115
Replace Saher Hamed with:
Saher Hamed Israel
G. Rossini United States
Yun Luan China
Nan Jia China
Jie Cheng China
Yiming Wang Canada
Cristian Turato Italy
Alfredo Procino Italy
Feng Xue China
Bing Tu China
Yifen Shi relative to Saher Hamed Israel Saher Hamed's profile →
Citations per field
00.5×6.7×
Saher Hamed · 1×
Citations per year

Countries citing papers authored by Yifen Shi

Since Specialization
Citations

This map shows the geographic impact of Yifen Shi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yifen Shi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yifen Shi more than expected).

Fields of papers citing papers by Yifen Shi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yifen Shi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yifen Shi. The network helps show where Yifen Shi may publish in the future.

Co-authorship network of co-authors of Yifen Shi

This figure shows the co-authorship network connecting the top 25 collaborators of Yifen Shi. A scholar is included among the top collaborators of Yifen Shi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yifen Shi. Yifen Shi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 1
2 1
3 11
4 5
5 20
6 10
7 1
8 9
9 89
10 16
11
Exosome secreted from adipose-derived stem cells attenuates diabetic nephropathy by promoting autophagy flux and inhibiting apoptosis in podocytebreakdown →
289
12 89
13 26
14 66
15 20
16 11
17 9
18 20
19 57
20 13

About Yifen Shi

Yifen Shi is a scholar working on Hematology, Genetics and Geriatrics and Gerontology, having authored 33 papers that have together received 888 indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (7 papers), Cancer-related molecular mechanisms research (4 papers) and Acute Myeloid Leukemia Research (4 papers). The work is most often cited by research in Hematology (181 citations), Cancer Research (239 citations) and Rehabilitation (75 citations). Yifen Shi has collaborated with scholars based in China, United States and Hong Kong. Frequent co-authors include He Huang, Yiwen Li, Li Zhao, Qiang He, Jianguang Gong, Juan Jin, Wen Liu, Guanghui Xi, Yakai Feng and Bin Liang. Their work appears in journals such as PLoS ONE, Scientific Reports and Carbohydrate Polymers.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026